Patients must not have any known allergy or reaction to any component of the durvalumab (MEDI) and/or tremelimumab formulation
Known hypersensitivity to any component of the formulation or substituted benzimidazoles
Patients who have exhibited allergic reactions to a similar structural compound or to a formulation component of CX-.
Known hypersensitivity or allergy to murine products or any component of the obinutuzumab, rituximab, idasanutlin, or venetoclax formulation
History of hypersensitivity to any of the additives in the alectinib drug formulation
History of hypersensitivity reactions to study drug or any component of the study drug formulation
Known allergy or reaction to any component of either study drug formulation
Known allergy or hypersensitivity to any component of the atezolizumab formulation
Known hypersensitivity to immunoglobulins or to any other component of the IP formulation
Known allergy or reaction to any component of either study drug formulation
History of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid
Known allergy or reaction to any component of either study drug formulation
Known hypersensitivity to immunoglobulins or to any other component of the IP formulation
Has known allergy or reaction to any component of either study drug or formulation components
Known hypersensitivity or allergy to any component of the avelumab formulation
History of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid
History of hypersensitivity to any component of the formulation
Has known hypersensitivity to pembrolizumab (MK-) or its formulation
Known allergy or reaction to any component of the MEDI formulation or its excipients
History of hypersensitivity to vandetanib, lactose, murine products, or any component of the formulation
History of hypersensitivity to any component of the formulation
History of hypersensitivity to bevacizumab, murine products, or any component of the formulation
History of hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate , or to any component of the formulation
History of hypersensitivity to cetuximab, murine products, or any component of the formulation
History of hypersensitivity to any component of the formulation
Patients who have exhibited allergic reactions to a similar structural compound or to a formulation component.
DOSE ESCALATION COHORT: Known allergy or reaction to any component of either study drug formulation; any history of serotonin syndrome (SS) after receiving  or more serotonergic drugs
DOSE EXPANSION COHORT: Known allergy or reaction to any component of either study drug formulation; any history of serotonin syndrome (SS) after receiving  or more serotonergic drugs
Hypersensitivity to pembrolizumab or any of its excipients, or a known history of hypersensitivity to IL- or any component of the formulation
Hypersensitive or intolerant to any component of the study drug(s) formulation
Previous monoclonal antibody (mAb) or other treatment specifically directed against CD; history of serious allergy or reaction to any component of the MEDI- formulation that would prevent administration
Patients with a history of hypersensitivity to sirolimus or any component of the formulation.
Patients must not have any known allergy or reaction to any component of the MEDI formulation
Known allergy or hypersensitivity to any component of the atezolizumab formulation
Known allergy or hypersensitivity to any component of the bevacizumab formulation
Known allergy or past administration reaction including infusion related reaction (IRRs), anaphylactic, or anaphylactoid reactions to any component of the CDX- formulation.
History of hypersensitivity to any of the additives in the alectinib and crizotinib drug formulation
History of hypersensitivity to any component of the formulation.
Known hypersensitivity to capecitabine, fluorouracil, or any component of the formulation
Known hypersensitivity to ibrutinib or any component of the ibrutinib formulation
Known immediate or delayed hypersensitivity reaction to carboplatin, paclitaxel, polysorbate , or any other component of the formulation
Known hypersensitivity to any component of the formulation
History of hypersensitivity to any component of the formulation
History of hypersensitivity to bevacizumab or murine products, temsirolimus or its metabolites, or any component of the formulation
CARBOPLATIN ARM: hypersensitivity to carboplatin or any component of the formulation
History of hypersensitivity to bevacizumab, murine products, or any component of the formulation
History of allergy or reaction to any component of the MEDI- formulation
Severe hypersensitivity reaction to treatment with another monoclonal antibody, known or suspected hypersensitivity to study drugs or any component of their formulation.
Subject has known history of serious hypersensitivity reaction to ASP, or any component of the formulation used.
History of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid
Known hypersensitivity to any component of atezolizumab formulation or other study medication
Subject has a known history of serious hypersensitivity to ASP, or any component of the formulation used.
Known allergy or hypersensitivity to any component of the formulation of CA- used in this study
Subject has known history of serious hypersensitivity reaction to ASP, or any component of the formulation used.
Patients with known hypersensitivity to NT-I or any component used in the vehicle/formulation are ineligible
History of hypersensitivity or allergic reaction to NRT, or any component of its formulation
Has received any formulation of POS within prior  days
Known hypersensitivity to gemcitabine or any component of the formulation.
